CACLP - The largest IVD Expo & Conference

Angle, Eisai Agree to Study HER2 Assay

Industry news | 03 January, 2024 | CACLP

Original from: 360dx

 

UK-based liquid biopsy firm Angle said Tuesday that it inked an agreement with drug firm Eisai to conduct a pilot study on the use of Angle's HER2 assay to guide treatment of breast cancer patients with HER2-expressing solid tumors.

 

The study, for which Angle will receive $250,000, will evaluate the use of Angle's Portrait HER2 assay to evaluate breast cancer patients' HER2 status in a Phase II study of the HER2-targeting antibody-drug conjugate BB-1701. Angle's Portrait HER2 assay provides quantitative determination of HER2 protein expression and HER2/neu gene amplification in circulating tumor cells, and it is used to identify patients who could benefit from anti-HER2 ADC therapy, which Tokyo-based Eisai is codeveloping with China-based Bliss Biopharmaceutical.

 

"Angle's Portrait HER2 assay provides a way to evaluate HER2 status in patients where a tissue biopsy at the metastatic site either fails or is not feasible," Angle CEO Andrew Newland said in a statement. "We are delighted that Eisai is utilizing our new HER2 assay for this study and believe that a successful pilot study will lead the way to major expansion of this line of our business going forward."

 

Angle said the pilot study also could lead to larger-scale follow-up studies.

​​

Source: Angle, Eisai Agree to Study HER2 Assay

 

Press contact CACLP - The largest IVD Expo & Conference

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

  • Name *
  • Email *
  • Company name *
  • Country *
    CACLP - The largest IVD Expo & Conference

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Share
Opening Countdown
0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

CACLP - The largest IVD Expo & Conference